Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Immix Biopharma ( (IMMX) ).
On June 3, 2025, Immix Biopharma, Inc. entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC to offer and sell shares of its common stock at its discretion. This agreement allows the company to raise capital through the sale of shares, with the agent receiving a 3% commission on sales, potentially impacting the company’s financial flexibility and market operations.
The most recent analyst rating on (IMMX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Immix Biopharma stock, see the IMMX Stock Forecast page.
More about Immix Biopharma
Average Trading Volume: 155,164
Technical Sentiment Signal: Buy
Current Market Cap: $72.48M
For detailed information about IMMX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue